Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression - PubMed (original) (raw)
Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression
Jingrui Jiang et al. Cancer Res. 2005.
Abstract
Epidermal growth factor receptor (EGFR) plays critical roles in many biological processes and in tumorigenesis. Here, we show that two mutated EGFRs found in lung and other malignancies, EGFR-G719S and EGFR-L858R, could transform Ba/F3 cells to interleukin-3 (IL-3)-independent growth, in a ligand-independent manner, an activity associated with the transforming function of other mutated tyrosine kinases. The mutated receptors are autophosphorylated in the absence of IL-3 without EGF stimulation, and their expression led to the constitutive activation of signal transducers and activators of transcription 5, extracellular signal-regulated kinase 1/2 (ERK1/2), ERK5, and AKT. In wild-type EGFR-expressing Ba/F3 cells, the major EGF-mediated signaling pathways were still intact. Gefitinib inhibited the growth of mutant EGFR-transformed Ba/F3 cells. Strikingly, the gefitinib sensitivity of cells expressing the L858R mutant was significantly greater than that of cells expressing the G719S mutant form, suggesting that distinct EGFR mutations may be differentially sensitive to small-molecule inhibitors. Furthermore, our data showed an antiproliferative effect of gefitinib on the EGFR-transformed Ba/F3 cells. Our results provide a model system to study the function of mutated EGFR and the differential effects of pharmacologic EGFR inhibition on the distinct mutant forms of this tyrosine kinase.
Similar articles
- Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
Sato M, Vaughan MB, Girard L, Peyton M, Lee W, Shames DS, Ramirez RD, Sunaga N, Gazdar AF, Shay JW, Minna JD. Sato M, et al. Cancer Res. 2006 Feb 15;66(4):2116-28. doi: 10.1158/0008-5472.CAN-05-2521. Cancer Res. 2006. PMID: 16489012 - An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.
Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B. Kobayashi S, et al. Cancer Res. 2005 Aug 15;65(16):7096-101. doi: 10.1158/0008-5472.CAN-05-1346. Cancer Res. 2005. PMID: 16103058 - Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA Jr. Helfrich BA, et al. Clin Cancer Res. 2006 Dec 1;12(23):7117-25. doi: 10.1158/1078-0432.CCR-06-0760. Clin Cancer Res. 2006. PMID: 17145836 - Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs.
Ono M, Kuwano M. Ono M, et al. Clin Cancer Res. 2006 Dec 15;12(24):7242-51. doi: 10.1158/1078-0432.CCR-06-0646. Clin Cancer Res. 2006. PMID: 17189395 Review.
Cited by
- Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.
Hayes TK, Aquilanti E, Persky NS, Yang X, Kim EE, Brenan L, Goodale AB, Alan D, Sharpe T, Shue RE, Westlake L, Golomb L, Silverman BR, Morris MD, Fisher TR, Beyene E, Li YY, Cherniack AD, Piccioni F, Hicks JK, Chi AS, Cahill DP, Dietrich J, Batchelor TT, Root DE, Johannessen CM, Meyerson M. Hayes TK, et al. Nat Commun. 2024 Mar 28;15(1):2742. doi: 10.1038/s41467-024-45594-4. Nat Commun. 2024. PMID: 38548752 Free PMC article. - Measuring Drug Response with Single-Cell Growth Rate Quantification.
Xu FX, Wu R, Hu K, Fu D. Xu FX, et al. Anal Chem. 2023 Dec 12;95(49):18114-18121. doi: 10.1021/acs.analchem.3c03434. Epub 2023 Nov 28. Anal Chem. 2023. PMID: 38016067 - EGFR is a potential dual molecular target for cancer and Alzheimer's disease.
Choi HJ, Jeong YJ, Kim J, Hoe HS. Choi HJ, et al. Front Pharmacol. 2023 Aug 2;14:1238639. doi: 10.3389/fphar.2023.1238639. eCollection 2023. Front Pharmacol. 2023. PMID: 37601068 Free PMC article. Review. - HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function.
Mitani Y, Ohashi S, Kikuchi O, Nakai Y, Ida T, Mizumoto A, Yamamoto Y, Saito T, Kataoka S, Matsubara J, Yamada A, Kanai M, Matsumoto S, Sakai H, Yoshikawa K, Nakamura E, Muto M. Mitani Y, et al. Sci Rep. 2022 Jun 2;12(1):9213. doi: 10.1038/s41598-022-13189-y. Sci Rep. 2022. PMID: 35654814 Free PMC article. - Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer.
Farnsworth DA, Chen YT, de Rappard Yuswack G, Lockwood WW. Farnsworth DA, et al. Cells. 2021 Dec 16;10(12):3553. doi: 10.3390/cells10123553. Cells. 2021. PMID: 34944063 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous